Antigen Design Articles & Analysis
7 news found
Creative BioMart, a biotechnology company focused on protein-related research solutions, has recently upgraded its epitope mapping service to better support researchers in therapeutic antibody development, vaccine design, and immunogenicity studies. The updated platform integrates multiple experimental approaches with customizable strategies, enabling more accurate identification ...
By keeping up with the latest advancements in the field, its team of expert scientists possesses a deep knowledge of RNA biology, viral vectors, antigen design, and delivery systems. This expertise allows them to design and develop highly effective and safe mRNA vaccine candidates. ...
This edit knocks out B2M expression and eliminates endogenous HLA class I presentation on the surface of the CAR-T cells while enabling expression of the fusion transgene of HLA-E, a minor HLA class I antigen, designed to blunt both T- and NK-cell-mediated rejection of the CAR-T cell therapy by the patient’s immune system. The data demonstrate that, when ...
” In addition to the financing momentum, Prellis has recruited a pair of seasoned industry executives to support expansion of their EXIS platform: Kevin Chapman, PhD, formerly of Berkeley Lights, Inc. and Merck & Co., Inc., as Chief Scientific Officer Yelda Kaya, MBBS, LLB, MBA, formerly of J&J Innovation, GSK and Ashurst, as Chief Business Officer The EXIS platform ...
” In addition to the financing momentum, Prellis has recruited a pair of seasoned industry executives to support expansion of their EXIS platform: Kevin Chapman, PhD, formerly of Berkeley Lights, Inc. and Merck & Co., Inc., as Chief Scientific Officer Yelda Kaya, MBBS, LLB, MBA, formerly of J&J Innovation, GSK and Ashurst, as Chief Business Officer The EXIS platform ...
The first of two manuscripts has been published in "NPJ Vaccines" and provides data demonstrating that the company’s structure-guided antigen design and synthetic nanoparticle delivery platform has been used to generate a candidate vaccine (V-306) for prophylaxis against RSV infection. ...
Pepex Biomedical has diverted funds and resources to the development of Multiple Rapid Covid-19 Tests designed to accurately identify Antigens (diagnostic to detect active virus) and Antibodies (to determine immunity) in under 15 minutes with 95% accuracy ...